Showing 1801-1810 of 2050 results for "".
- Glaukos’ iDose TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Studyhttps://modernod.com/news/glaukos-idose-tr-demonstrates-sustained-iop-reduction-and-favorable-safety-profile-over-24-months-in-phase-2b-study/2478753/Glaukos announced that its iDose TR sustained-release travoprost implant continued to provide sustained substantial reductions in IOP in a 24-month interim analysis of the ongoing 36-month phase 2b clinical trial conducted under a U.S. investigational new drug (IND) protocol. Administered
- Aviceda Therapeutics Announces Formation of Executive Teamhttps://modernod.com/news/aviceda-therapeutics-announces-formation-of-executive-team/2478745/Aviceda Therapeutics has announced the composition of the Executive Team that will guide the company through ongoing development of first-in-class therapeutics and continued growth opportunities as a business entity. Aviceda’s lead ophthalmic optimized nanoparticle, as an intravitreal form
- Ocular Therapeutix Promotes Michael Goldstein, MD, MBA, to President, Ophthalmologyhttps://modernod.com/news/ocular-therapeutix-promotes-michael-goldstein-md-mba-to-president-ophthalmology/2478733/Ocular Therapeutix announced the promotion of Michael Goldstein, MD, MBA, to the newly created position of President, Ophthalmology. Dr. Goldstein will continue to report to Antony Mattessich, Ocular’s President and Chief Executive Officer. With this promotion, Dr. Goldstein will be responsible f
- Vaccine Rollout On Track, Expect 300M Doses Through March: Fedshttps://modernod.com/news/vaccine-rollout-on-track-expect-300m-doses-through-march-feds/2478672/If the initial success of the Pfizer-BioNTech rollout continues, and emergency use authorization (EAU) is granted to Moderna and Johnson & Johnson vaccines in development, Operation Warp Speed officials expect to have 300 million doses of COVID-19 vaccines to distribute across the United Stat
- VSY Biotechnology Introduces Protectalon DUO OVD Kithttps://modernod.com/news/vsy-biotechnology-introduces-protectalon-duo-ovd-kit/2478673/VSY Biotechnology has launched Protectalon Duo, which aims to meet OVD needs at different stages of cataract surgery with a single kit. The dual pack contains high filling volume of one unit cohesive (14 mg/mL, 1.1 mL) and one unit dispersive (30 mg/ml, 1.1 ml). “NaHA-based OVDs prov
- Bruder Introduces Pre-Surgical Patient Prep Kithttps://modernod.com/news/bruder-introduces-pre-surgical-patient-prep-kit/2478655/Bruder has introduced the Bruder Sx Pre-Surgical Patient Prep Kit, which allow patients’ hygiene products to be available in a single, self-contained kit. Doctors can provide the kit directly in their practices
- CureVac Commences Global Pivotal Phase 2b/3 Trial for COVID-19 Vaccine Candidate, CVnCoVhttps://modernod.com/news/curevac-commences-global-pivotal-phase-2b-3-trial-for-covid-19-vaccine-candidate-cvncov/2478656/CureVac announced that it has enrolled the first participant in the pivotal phase 2b/3 study of its mRNA vaccine candidate, CVnCoV, against COVID-19. The randomized, observer blind, placebo-controlled phase 2b/3 trial
- Alsanza Announces Global Launch of Alsee Zero Glistening, Zero Haze Hydrophobic Monofocal IOLhttps://modernod.com/news/alsanza-globally-launches-zero-glistening-zero-haze-hydrophobic-monofocal-iol-alsee/2478652/Germany-based Alsanza announced the launch of the Alsee Zero Glistening Zero Haze Hydrophobic Monofocal IOL. The Alsee IOL is developed and designed to provide long-term clarity and high-contrast sensitive quality of vision with its 24-hour aspheric optic design. Alsee Zero Glistening Zero
- Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aldeyra-announces-first-patient-enrolled-in-the-phase-3-tranquility-trial-of-reproxalap-for-the-treatment-of-dry-eye-disease/2478638/Aldeyra Therapeutics announced enrollment of the first patient in the phase 3 TRANQUILITY trial of 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease. The multicenter randomized, double-masked, parallel design, vehicle-controlled clinical trial will assess the effica
- InMed Licenses MiDROPS Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoidshttps://modernod.com/news/inmed-licenses-midrops-delivery-technology-from-eyecro-for-the-delivery-of-therapeutic-cannabinoids/2478621/InMed Pharmaceuticals announced that it has secured an exclusive, worldwide license from EyeCRO for its Microemulsion Drug Ocular Penetration System (MiDROPS) eyedrop delivery technology targeting effective, topical administration of cannabinoids to the eye. EyeCRO is a contract research o